![Western Blot: RIPK1/RIP1 Antibody [NBP1-77077] - At 6 h after CCI, RIP1 protein levels in the cortex detected by western blotting were decreased in Nec-1 and melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. Values are represented as means +/- SEM (n = 3). B-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey's test. *P < 0.05 and **P < 0.01 vs. CCI group. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fnmol.2019.00222/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Western-Blot-NBP1-77077-img0005.jpg "Western Blot: RIPK1/RIP1 Antibody [NBP1-77077] - At 6 h after CCI, RIP1 protein levels in the cortex detected by western blotting were decreased in Nec-1 and melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. Values are represented as means +/- SEM (n = 3). B-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey's test. *P < 0.05 and **P < 0.01 vs. CCI group. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fnmol.2019.00222/full) licensed under a CC-BY license.")
| Reactivity | Hu, Mu, RtSpecies Glossary |
| Applications | WB, ELISA, ICC/IF, IHC, KD |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Format | BSA Free |
| Concentration | 1 mg/ml |
| Immunogen | Antibody was raised against a 15 amino acid synthetic peptide from near the amino terminus of human RIPK1. The immunogen is located within amino acids 180 - 230 of RIPK1. Amino Acid Squence: DVNAKPTEKSDVYS |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | RIPK1 |
| Purity | Peptide affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Theoretical MW | 70.7 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
||
| Control Peptide |
|
||
| Reviewed Applications |
|
||
| Publications |
|
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS |
| Preservative | 0.02% Sodium Azide |
| Concentration | 1 mg/ml |
| Purity | Peptide affinity purified |
![Western Blot FADD [p Ser194] Antibody (709736)](https://images.novusbio.com/images2/FADD_MAB7047_Western_Blot_11404.jpg)
![Immunocytochemistry FADD [p Ser194] Antibody (709736)](https://images.novusbio.com/images2/FADD_MAB7047_Immunocytochemistry_11450.jpg)
![Western Blot TRADD Antibody [Unconjugated]](https://images.novusbio.com/images2/TRADD_AF2658_Western_Blot_5202.jpg)
![Immunocytochemistry TRADD Antibody [Unconjugated]](https://images.novusbio.com/images2/TRADD_AF2658_Immunocytochemistry__Immunofluorescence_22493.jpg)
| Images | Ratings | Applications | Species | Date | Details | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
reviewed by:
Verified Customer |
IHC-P | Mouse | 12/24/2014 |
Summary
|
Secondary Antibodies |
Isotype Controls |
Research Areas for RIPK1/RIP1 Antibody (NBP1-77077)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Immunocytochemistry/Immunofluorescence: RIPK1/RIP1 Antibody [NBP1-77077] - Mouse Kidney cells with RIPK1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunofluorescence-NBP1-77077-img0003.jpg "Immunocytochemistry/Immunofluorescence: RIPK1/RIP1 Antibody [NBP1-77077] - Mouse Kidney cells with RIPK1 antibody at 20 ug/mL.")
![Immunohistochemistry: RIPK1/RIP1 Antibody [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). The expression of RIP1 was tested in NBT and TBI tissues from Jiangsu Province Hospital by immunohistochemistry. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fnmol.2019.00222/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-NBP1-77077-img0007.jpg "Immunohistochemistry: RIPK1/RIP1 Antibody [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). The expression of RIP1 was tested in NBT and TBI tissues from Jiangsu Province Hospital by immunohistochemistry. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fnmol.2019.00222/full) licensed under a CC-BY license.")
![Western Blot: RIPK1/RIP1 Antibody [NBP1-77077] - Rat kidney tissue lysate with RIPK1 antibody at 1 ug/mL.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Western-Blot-NBP1-77077-img0001.jpg "Western Blot: RIPK1/RIP1 Antibody [NBP1-77077] - Rat kidney tissue lysate with RIPK1 antibody at 1 ug/mL.")
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-77077] - Mouse kidney tissue with RIPK1 antibody at 2.5 ug/ml.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-Paraffin-NBP1-77077-img0002.jpg "Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-77077] - Mouse kidney tissue with RIPK1 antibody at 2.5 ug/ml.")
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-77077] - Staining of mouse kidney tissue with antibody at 2.5 ug/ml.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-NBP1-77077-img0004.jpg "Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-77077] - Staining of mouse kidney tissue with antibody at 2.5 ug/ml.")
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta -actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416171410.jpg "Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta -actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-31020241616014.jpg "Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-31020241618915.jpg "Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta -actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416175211.jpg "Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta -actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416163731.jpg "Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416163751.jpg "Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416163761.jpg "Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![N/A TNF RI/TNFRSF1A [HRP]](https://images.novusbio.com/images2/DATA_TNF_RI_DRT100_ELISA_815.jpg)
![N/A TNF RI/TNFRSF1A [HRP]](https://images.novusbio.com/images2/DATA_TNF_RI_DRT100_ELISA_816.jpg)
![N/A TNF RI/TNFRSF1A [HRP]](https://images.novusbio.com/images2/TNF_RI_DRT100_ELISA_175.jpg)
![Western Blot JNK1 Antibody (228601) [Unconjugated]](https://images.novusbio.com/images2/JNK1_MAB17761_Western_Blot_5991.jpg)
![Western Blot JNK1 Antibody (228601) [Unconjugated]](https://images.novusbio.com/images2/JNK1_MAB17761_Western_Blot_6327.jpg)
![Immunocytochemistry JNK1 Antibody (228601) [Unconjugated]](https://images.novusbio.com/images2/JNK1_MAB17761_Immunocytochemistry__Immunofluorescence_20184.jpg)
![Western Blot FLIP Antibody [Unconjugated]](https://images.novusbio.com/images2/FLIP_AF821_Western_Blot_5910.jpg)
![Immunocytochemistry Insulin Antibody (182410) [Unconjugated]](https://images.novusbio.com/images2/Insulin_MAB1417_Immunocytochemistry_9376.jpg)
![Immunohistochemistry Insulin Antibody (182410) [Unconjugated]](https://images.novusbio.com/images2/mab1417_human-bovine-mouse-insulin-mab-clone-182410-immunohistochemistry-308202115145.jpg)
![Bioactivity CTLA-4 [Unconjugated]](https://images.novusbio.com/images2/CTLA4_7268CT_2293.jpg)
![Immunocytochemistry Caspase-3 Antibody [Unconjugated] - Active](https://images.novusbio.com/images2/Caspase-3_AF835_Immunocytochemistry_6532.jpg)
![Immunohistochemistry Caspase-3 Antibody [Unconjugated] - Active](https://images.novusbio.com/images2/Caspase3_AF835_Immunohistochemistry_22976.jpg)
![Immunocytochemistry Caspase-3 Antibody [Unconjugated] - Active](https://images.novusbio.com/images2/Caspase-3_AF835_Immunocytochemistry_9340.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")